Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
December 20, 2003
Local complexity of amino acid interactions in a protein core
Rajul K Jain, Rama Ranganathan
Biomedicines
|
May 25, 2017
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment
Yilong Zhang, Rajul K Jain, Min Zhu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2010
Food and oral antineoplastics: more than meets the eye
Rajul K Jain, Satjit S Brar, Lawrence J Lesko
Journal of the National Cancer Institute
|
June 8, 2014
Response
Ilya G Glezerman, Mimi I Hu, Rajul K Jain
Journal of the National Cancer Institute
|
May 1, 2013
RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials
Rajul K Jain, J Jack Lee, David Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2013
Reply to A. Levy et al
Rajul K Jain, J Jack Lee, David Hong, et al.
Investigational New Drugs
|
July 28, 2010
A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors
Rajul K Jain, Donald L Trump, Merrill J Egorin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse
Rajul K Jain, J Jack Lee, David Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2012
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies
Rajul K Jain, J Jack Lee, Chaan Ng, et al.
Cell Cycle (Georgetown, Tex.)
|
October 16, 2015
Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies
Rajul K Jain, David S Hong, Aung Naing, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Proceedings of the National Academy of Sciences of the United States of America
|
December 20, 2003
Local complexity of amino acid interactions in a protein core
Rajul K Jain, Rama Ranganathan
Biomedicines
|
May 25, 2017
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment
Yilong Zhang, Rajul K Jain, Min Zhu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2010
Food and oral antineoplastics: more than meets the eye
Rajul K Jain, Satjit S Brar, Lawrence J Lesko
Journal of the National Cancer Institute
|
June 8, 2014
Response
Ilya G Glezerman, Mimi I Hu, Rajul K Jain
Journal of the National Cancer Institute
|
May 1, 2013
RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials
Rajul K Jain, J Jack Lee, David Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2013
Reply to A. Levy et al
Rajul K Jain, J Jack Lee, David Hong, et al.
Investigational New Drugs
|
July 28, 2010
A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors
Rajul K Jain, Donald L Trump, Merrill J Egorin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse
Rajul K Jain, J Jack Lee, David Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2012
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies
Rajul K Jain, J Jack Lee, Chaan Ng, et al.
Cell Cycle (Georgetown, Tex.)
|
October 16, 2015
Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies
Rajul K Jain, David S Hong, Aung Naing, et al.
Page
of 2